Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19. “We are proud to be contributing toward the effort to develop a COVID-19 vaccine. […]